{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:29:20Z","timestamp":1786735760639,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Niger Postgrad Med J"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/npmj.npmj_75_19","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T05:46:34Z","timestamp":1570167994000},"page":"195","source":"Crossref","is-referenced-by-count":11,"title":["Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir"],"prefix":"10.4103","volume":"26","author":[{"given":"MaxwellO","family":"Akanbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"OcheO","family":"Agbaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihedinachi","family":"Otoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PatriciaE","family":"Agaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolake","family":"Akinsola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Okolie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PlacidO","family":"Ugoagwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AliyuA","family":"Babadoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adewumi","family":"Adediran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FinomoO","family":"Finomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JonahO","family":"Abah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HarunaM","family":"Muktar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AlaniS","family":"Akanmu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1117-1936.268597-1","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1080\/14656566.2016.1232387","article-title":"Abacavir+dolutegravir+lamivudine for the treatment of HIV","author":"Comi","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.4103\/1117-1936.268597-2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00126334-200401010-00003","article-title":"The NEAT study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients","author":"Rodriguez-French","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.4103\/1117-1936.268597-3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1086\/424009","article-title":"Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults","author":"DeJesus","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/1117-1936.268597-4","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0149-2918(01)80132-6","article-title":"Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir","author":"Hetherington","year":"2001","journal-title":"Clin Ther"},{"key":"key-10.4103\/1117-1936.268597-5","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0149-2918(02)80057-1","article-title":"The abacavir hypersensitivity reaction: A review","author":"Clay","year":"2002","journal-title":"Clin Ther"},{"key":"key-10.4103\/1117-1936.268597-6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pbj.2016.12.004","article-title":"Prevalence of abacavir-associated hypersensitivity syndrome and HLA-B*5701 allele in a Portuguese HIV-positive population","author":"Carolino","year":"2017","journal-title":"Porto Biomed J"},{"key":"key-10.4103\/1117-1936.268597-7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"key-10.4103\/1117-1936.268597-8","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.aids.0000171414.99409.fb","article-title":"Clinical and immunogenetic correlates of abacavir hypersensitivity","author":"Phillips","year":"2005","journal-title":"AIDS"},{"key":"key-10.4103\/1117-1936.268597-9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/phgs.5.2.203.27481","article-title":"Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations","author":"Hughes","year":"2004","journal-title":"Pharmacogenomics"},{"key":"key-10.4103\/1117-1936.268597-10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/504874","article-title":"Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study","author":"Rauch","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/1117-1936.268597-11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1117-1936.268597-12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/cit757","article-title":"Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the infectious diseases society of America","author":"Aberg","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/1117-1936.268597-13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jac\/dkm243","article-title":"Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan","author":"Sun","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key-10.4103\/1117-1936.268597-14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/135965350801300508","article-title":"Incidence of abacavir hypersensitivity reactions in euroSIDA","author":"Bannister","year":"2008","journal-title":"Antivir Ther"},{"key":"key-10.4103\/1117-1936.268597-15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/INF.0b013e3182076864","article-title":"Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy","author":"Nahirya-Ntege","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.4103\/1117-1936.268597-16","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/QAD.0b013e32830719aa","article-title":"First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America","author":"Young","year":"2008","journal-title":"AIDS"},{"key":"key-10.4103\/1117-1936.268597-17","unstructured":"Gentra\u00ae Puregene\u00ae Handbook: QIAGEN; 2014. 4th ed.. Available from: https:\/\/www.qiagen.com\/us\/resources\/download.aspx?id=a9e6a609-4600-4b03-afbd-974318590ce5&lang=en. [Last accessed on 2017 Jun 22]."},{"key":"key-10.4103\/1117-1936.268597-18","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1093\/hmg\/dds226","article-title":"Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans","author":"McLaren","year":"2012","journal-title":"Hum Mol Genet"},{"key":"key-10.4103\/1117-1936.268597-19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jinf.2017.09.007","article-title":"Prevalence of HLA-B*5701 in a Kenyan population with HIV infection","author":"Shah","year":"2018","journal-title":"J Infect"},{"key":"key-10.4103\/1117-1936.268597-20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-3156.2010.02688.x","article-title":"Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART","author":"Munderi","year":"2011","journal-title":"Trop Med Int Health"}],"container-title":["Nigerian Postgraduate Medical Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:33:16Z","timestamp":1786732396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/npmj.npmj_75_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"alternative-id":["268597"],"URL":"https:\/\/doi.org\/10.4103\/npmj.npmj_75_19","relation":{},"ISSN":["1117-1936"],"issn-type":[{"value":"1117-1936","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}